Literature DB >> 28835317

miR-216a-3p Inhibits the Proliferation, Migration, and Invasion of Human Gastric Cancer Cells via Targeting RUNX1 and Activating the NF-κB Signaling Pathway.

Yinfang Wu1, Jun Zhang2, Yu Zheng3, Cheng Ma3, Xing-E Liu4, Xiaodong Sun1.   

Abstract

This work aims to elucidate the effects and the potential underlying mechanisms of microRNA-216a-3p (miR-216a-3p) on the proliferation, migration, and invasion of gastric cancer (GC) cells. In this study, we revealed that the expression of miR-216a-3p was significantly elevated in GC tissues and cell lines. The different expression level of miR-216a-3p was firmly correlated with clinicopathological characteristics of GC patients. We next demonstrated that upregulation of miR-216a-3p could dramatically promote the ability of proliferation, migration, and invasion of GC cells using a series of experiments, whereas downregulation essentially inhibited these properties. Additionally, through bioinformatics analysis and biological approaches, we confirmed that runt-related transcription factor 1 (RUNX1) was a direct target of miR-216a-3p, and overexpression of RUNX1 could reverse the potential effect of miR-216a-3p on GC cells. Furthermore, mechanistic investigation using Western blot analysis showed that downregulation of RUNX1 by miR-216a-3p could stimulate the activation of NF-κB signaling pathway. In summary, this work proved that miR-216a-3p can promote GC cell proliferation, migration, and invasion via targeting RUNX1 and activating the NF-κB signaling pathway. Therefore, miR-216a-3p/RUNX1 could be a possible molecular target for innovative therapeutic agents against GC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28835317     DOI: 10.3727/096504017X15031557924150

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  9 in total

1.  Circular RNA profile of infantile hemangioma by microarray analysis.

Authors:  Cong Fu; Renrong Lv; Guangqi Xu; Linfeng Zhang; Jianhai Bi; Li Lin; Xiaowen Liu; Ran Huo
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

2.  miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1.

Authors:  Shichao Han; Jinming Zhu; Yilei Zhang
Journal:  Med Sci Monit Basic Res       Date:  2018-02-15

3.  TIPRL, a Novel Tumor Suppressor, Suppresses Cell Migration, and Invasion Through Regulating AMPK/mTOR Signaling Pathway in Gastric Cancer.

Authors:  Meng Luan; Shan-Shan Shi; Duan-Bo Shi; Hai-Ting Liu; Ran-Ran Ma; Xiao-Qun Xu; Yu-Jing Sun; Peng Gao
Journal:  Front Oncol       Date:  2020-07-03       Impact factor: 6.244

4.  miR-216a-5p inhibits malignant progression in small cell lung cancer: involvement of the Bcl-2 family proteins.

Authors:  Yanqin Sun; Bingshuang Hu; Yanhong Wang; Zhen Li; Jingfang Wu; Yunchu Yang; Yue Wei; Xiaofeng Peng; Hongling Chen; Rongqi Chen; Pingyan Jiang; Sixian Fang; Zhiwu Yu; Linlang Guo
Journal:  Cancer Manag Res       Date:  2018-10-18       Impact factor: 3.989

Review 5.  Cascades between miRNAs, lncRNAs and the NF-κB signaling pathway in gastric cancer (Review).

Authors:  Risheng Chen; Mingxiu Yang; Weiguo Huang; Baiyun Wang
Journal:  Exp Ther Med       Date:  2021-05-17       Impact factor: 2.447

Review 6.  The Molecular Roles and Clinical Implications of Non-Coding RNAs in Gastric Cancer.

Authors:  Yanping Yue; Xinrong Lin; Xinyue Qiu; Lei Yang; Rui Wang
Journal:  Front Cell Dev Biol       Date:  2021-12-13

7.  Knockdown long non-coding RNA HCP5 enhances the radiosensitivity of esophageal carcinoma by modulating AKT signaling activation.

Authors:  Yue Guo; Lan Wang; Hui Yang; Nannan Ding
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

8.  Prediction of gastric cancer risk: association between ZBTB20 genetic variance and gastric cancer risk in Chinese Han population.

Authors:  Fei Bai; Ke Xiao
Journal:  Biosci Rep       Date:  2020-09-30       Impact factor: 3.840

Review 9.  Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges.

Authors:  Yang Yang; Xueting Deng; Quanpeng Li; Fei Wang; Lin Miao; Qi Jiang
Journal:  Cancer Commun (Lond)       Date:  2020-11-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.